The GLP-1 RA liraglutide has been demonstrated to exert a positive influence on LDL cholesterol and associated cardiovascular risk factors by diminishing oxidized LDL-induced endothelial dysfunction, enhancing dyslipidaemia, and augmenting the catabolism of apoB-containing lipoproteins [8,24]. Here, APOB is linked to endothelial dysfunction.